A Ten-gene Signature-based Risk Assessment Model Predicts the Prognosis of Lung Adenocarcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Aug 22

PMID 32819300

Citations 24

Authors

Hanliang Jiang

Shan Xu

Chunhua Chen

Affiliations

Soon will be listed here.

Abstract

Background: Lung adenocarcinoma (LUAD) is a major cause of cancer death. Therefore, identifying potential prognostic risk factors is critical to improve the survival of patients with LUAD.

Methods: Here, relevant datasets were downloaded from TCGA and GEO databases to screen the differentially expressed genes (DEGs). Univariate Cox analysis, LASSO regression analysis and multivariate Cox analysis were conducted on the DEGs combined with TCGA clinical data, and finally a risk assessment model based on 10 feature genes was constructed.

Results: The prognosis of patients was evaluated after the patients were grouped based on the median risk score and the results showed that the survival time of patients in the high-risk group was significantly shorter than that in the low-risk group. ROC analysis showed that the AUC values of the 1, 3, 5-year survival were 0.753, 0.724, and 0.73, respectively, indicating that the model was precise in predicting the prognosis, which was also verified in the external dataset GSE72094. In addition, a significant correlation was found between the risk score and the clinical stages of LUAD, that is, a later stage always corresponded to a higher risk score. Then, we performed survival analysis on the 10 feature genes independently in the TCGA-LUAD dataset through the GEPIA database, finding that the high expression of 6 genes (COL5A2, PLEK2, BAIAP2L2, S100P, ZIC2, SFXN1) was associated with the poor prognosis of LUAD patients.

Conclusion: To sum, this study established a 10-gene risk assessment model and further evaluated its value in predicting LUAD prognosis, which provided a new method for the prognosis prediction of LUAD.

Citing Articles

Integrated analysis of the role of PR/SET domain 14 in gastric cancer.

Li X, Wang C, Wang Y, Chen X, Li Z, Wang J BMC Cancer. 2024; 24(1):685.

PMID: 38840106 PMC: 11151633. DOI: 10.1186/s12885-024-12424-1.

Comprehensive analysis of Cuproplasia and immune microenvironment in lung adenocarcinoma.

Kuang J, Zheng Z, Ma W, Zeng S, Wu D, Weng X Front Pharmacol. 2023; 14:1240736.

PMID: 37781711 PMC: 10540310. DOI: 10.3389/fphar.2023.1240736.

DSCC1 interacts with HSP90AB1 and promotes the progression of lung adenocarcinoma via regulating ER stress.

Lin X, Liu Y, Zhang H, Wu L, Li Q, Deng J Cancer Cell Int. 2023; 23(1):208.

PMID: 37742009 PMC: 10518103. DOI: 10.1186/s12935-023-03047-w.

Identification of an optimized glycolytic-related risk signature for predicting the prognosis in breast cancer using integrated bioinformatic analysis.

Jiang D, Zhang L, Wang D, Liu Y Medicine (Baltimore). 2023; 102(35):e34715.

PMID: 37656998 PMC: 10476720. DOI: 10.1097/MD.0000000000034715.

Lipid Metabolism-Related Gene Markers Used for Prediction Prognosis, Immune Microenvironment, and Tumor Stage of Pancreatic Cancer.

Shu Y, Huang H, Gao M, Xu W, Cao X, Jia X Biochem Genet. 2023; 62(2):931-949.

PMID: 37505298 PMC: 11031448. DOI: 10.1007/s10528-023-10457-y.

References

Peng C, Chen H, Wallwiener M, Modugno C, Cuk K, Madhavan D . Plasma S100P level as a novel prognostic marker of metastatic breast cancer. Breast Cancer Res Treat. 2016; 157(2):329-338. DOI: 10.1007/s10549-016-3776-1. View

Villanueva N, Bazhenova L . New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis. 2018; 12:1753466618794133. PMC: 6144513. DOI: 10.1177/1753466618794133. View

Peng F, Wang R, Zhang Y, Zhao Z, Zhou W, Chang Z . Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol Cancer. 2017; 16(1):98. PMC: 5461634. DOI: 10.1186/s12943-017-0666-z. View

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

Shen Z, Zhao K, Du T . HOXA10 promotes nasopharyngeal carcinoma cell proliferation and invasion via inducing the expression of ZIC2. Eur Rev Med Pharmacol Sci. 2017; 21(5):945-952. View

Liu C, Li Y, Wei M, Zhao L, Yu Y, Li G . Identification of a novel glycolysis-related gene signature that can predict the survival of patients with lung adenocarcinoma. Cell Cycle. 2019; 18(5):568-579. PMC: 6464579. DOI: 10.1080/15384101.2019.1578146. View

Hanna N, Johnson D, Temin S, Baker Jr S, Brahmer J, Ellis P . Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(30):3484-3515. DOI: 10.1200/JCO.2017.74.6065. View

Hamaguchi N, Ihara S, Ohdaira T, Nagano H, Iwamatsu A, Tachikawa H . Pleckstrin-2 selectively interacts with phosphatidylinositol 3-kinase lipid products and regulates actin organization and cell spreading. Biochem Biophys Res Commun. 2007; 361(2):270-5. DOI: 10.1016/j.bbrc.2007.06.132. View

Rehbein G, Simm A, Hofmann H, Silber R, Bartling B . Molecular regulation of S100P in human lung adenocarcinomas. Int J Mol Med. 2008; 22(1):69-77. View

10.

Wang Y, Yang H, Shi X, Wang Y . Upregulation of microRNA-129-5p inhibits cell invasion, migration and tumor angiogenesis by inhibiting ZIC2 via downregulation of the Hedgehog signaling pathway in cervical cancer. Cancer Biol Ther. 2018; 19(12):1162-1173. PMC: 6301807. DOI: 10.1080/15384047.2018.1491497. View

11.

Imai H, Kaira K, Minato K . Clinical significance of post-progression survival in lung cancer. Thorac Cancer. 2017; 8(5):379-386. PMC: 5582459. DOI: 10.1111/1759-7714.12463. View

12.

Lu S, Zhang C, Luo R, Wang C, Liu L, Fu J . Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma. Cancer Lett. 2017; 402:71-80. DOI: 10.1016/j.canlet.2017.05.018. View

13.

Zhou C, Yao L . Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature. J Thorac Oncol. 2016; 11(2):174-86. DOI: 10.1016/j.jtho.2015.10.002. View

14.

Chalela R, Curull V, Enriquez C, Pijuan L, Bellosillo B, Gea J . Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. J Thorac Dis. 2017; 9(7):2142-2158. PMC: 5542927. DOI: 10.21037/jtd.2017.06.20. View

15.

Luo W, Wang Z, Zhang X . Identification of four differentially methylated genes as prognostic signatures for stage I lung adenocarcinoma. Cancer Cell Int. 2018; 18:60. PMC: 5909272. DOI: 10.1186/s12935-018-0547-6. View

16.

Gridelli C, Rossi A, Carbone D, Guarize J, Karachaliou N, Mok T . Non-small-cell lung cancer. Nat Rev Dis Primers. 2016; 1:15009. DOI: 10.1038/nrdp.2015.9. View

17.

Chen H, Tseng Y, Shu C, Weng T, Liou H, Yen L . Differential clinical significance of COL5A1 and COL5A2 in tongue squamous cell carcinoma. J Oral Pathol Med. 2019; 48(6):468-476. DOI: 10.1111/jop.12861. View

18.

Chiou J, Su C, Jan Y, Yang C, Huang M, Yu Y . Decrease of FSTL1-BMP4-Smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma. Sci Rep. 2017; 7(1):9830. PMC: 5575295. DOI: 10.1038/s41598-017-10366-2. View

19.

Ni M, Shi X, Qu Z, Jiang H, Chen Z, Hu J . Epithelial mesenchymal transition of non-small-cell lung cancer cells A549 induced by SPHK1. Asian Pac J Trop Med. 2015; 8(2):142-6. DOI: 10.1016/S1995-7645(14)60305-9. View

20.

Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z . Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 2017; 393:40-51. DOI: 10.1016/j.canlet.2017.02.016. View